NYSE:CYBN Cybin (CYBN) Stock Price, News & Analysis → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free CYBN Stock Alerts $0.35 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.3550-Day Range N/A52-Week Range$0.21▼$0.74Volume1.64 million shsAverage Volume2.44 million shsMarket Capitalization$143.80 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends Get Cybin alerts: Email Address Cybin MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,328.6% Upside$5.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.21) to ($0.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.94 out of 5 starsMedical Sector835th out of 928 stocksPharmaceutical Preparations Industry397th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingCybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCybin has only been the subject of 1 research reports in the past 90 days.Read more about Cybin's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CYBN. Previous Next 0.0 Dividend Strength Dividend YieldCybin does not currently pay a dividend.Dividend GrowthCybin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYBN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Cybin this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for CYBN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows33 people have added Cybin to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cybin insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.94% of the stock of Cybin is held by institutions.Read more about Cybin's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cybin are expected to grow in the coming year, from ($0.21) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cybin is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cybin is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCybin has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About CybinCybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.Read More CYBN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYBN Stock News HeadlinesMay 29, 2024 | businesswire.comCybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024May 14, 2024 | businesswire.comCybin to Participate in the Alliance Global Partners Healthcare Company ShowcaseSee More Headlines Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/02/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:CYBN CUSIPN/A CIK1833141 Webwww.cybin.com Phone908-764-8385FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,328.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.05% Return on Assets-97.85% Debt Debt-to-Equity RatioN/A Current Ratio5.76 Quick Ratio5.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book1.84Miscellaneous Outstanding Shares410,860,000Free Float349,227,000Market Cap$143.80 million OptionableN/A Beta0.50 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key CompetitorsSavaraNASDAQ:SVRAALX OncologyNASDAQ:ALXOOlema PharmaceuticalsNASDAQ:OLMATravere TherapeuticsNASDAQ:TVTXPepGenNASDAQ:PEPGView All CompetitorsInstitutional OwnershipRA Capital Management L.P.Bought 58,139,535 shares on 5/17/2024Ownership: 14.151%Ikarian Capital LLCBought 13,953,488 shares on 5/17/2024Ownership: 3.396%AWM Investment Company Inc.Bought 2,250,000 shares on 5/16/2024Ownership: 0.548%PEAK6 Investments LLCBought 228,716 shares on 5/15/2024Ownership: 0.056%View All Institutional Transactions CYBN Stock Analysis - Frequently Asked Questions Should I buy or sell Cybin stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYBN shares. View CYBN analyst ratings or view top-rated stocks. What is Cybin's stock price target for 2024? 1 Wall Street analysts have issued 12 month price targets for Cybin's shares. Their CYBN share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,328.6% from the stock's current price. View analysts price targets for CYBN or view top-rated stocks among Wall Street analysts. How have CYBN shares performed in 2024? Cybin's stock was trading at $0.35 on January 1st, 2024. Since then, CYBN stock has increased by 0.0% and is now trading at $0.35. View the best growth stocks for 2024 here. What ETF holds Cybin's stock? Simplify Propel Opportunities ETF holds 500,000 shares of CYBN stock, representing 0.18% of its portfolio. Who are Cybin's major shareholders? Cybin's stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (14.15%), Ikarian Capital LLC (3.40%), AWM Investment Company Inc. (0.55%) and PEAK6 Investments LLC (0.06%). How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CYBN) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
